SCHEMBL2535841

SCHEMBL2535841

NC(=O)C1CC[CH]CCCC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 2/20 0.41
MAPT P10636 1/20 0.41
ATM Q13315 1/20 0.41
CYP2D6 P10635 1/20 0.41
CES2 O00748 1/20 0.37
CES1 P23141 1/20 0.37
NOS2 P35228 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
EPHX1 P07099 2/20 0.34
HDAC8 Q9BY41 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
GAA P10253 2/20 0.32
GLA P06280 1/20 0.32
HSD17B10 Q99714 1/20 0.32
CYP2C19 P33261 1/20 0.32
ALDH1A1 P00352 2/20 0.32
CYP3A4 P08684 1/20 0.32
TSHR P16473 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2539833 0.93 KDM4E (0.42) KMT2AKDM4EMAPTATMCYP2D6
SCHEMBL2539204 0.89 KDM4E (0.45) KMT2AKDM4EMAPTATMCYP2D6
SCHEMBL1385858 0.89
SCHEMBL2537996 0.87 KMT2A (0.41) KMT2AKDM4EMAPTATMCYP2D6
Hydrochloric Acid SCHEMBL27755494 0.86 SMN1; SMN2 (0.40) KMT2AKDM4EMAPTATMCYP2D6
SCHEMBL2534890 0.85 CES2 (0.41) KMT2AKDM4EMAPTATMCYP2D6
SCHEMBL176610 0.81
SCHEMBL2541559 0.80
SCHEMBL28294126 0.80 TSHR (0.39) KDM4ECES2CES1SMN1; SMN2HDAC8
SCHEMBL25485911 0.78 CES2 (0.58) KMT2AKDM4EMAPTATMCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1642898-B1 HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE MSD KK (JP) 2013-03-27 EP disclosed
US-8044070-B2 Heteroaryloxy nitrogenous saturated heterocyclic derivative MSD K.K. (JP) 2011-10-25 US disclosed
US-20100210637-A1 HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE MSD K.K. (JP) 2010-08-19 US disclosed
US-7595316-B2 Heteroaryloxy nitrogenous saturated heterocyclic derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-09-29 US disclosed
US-20060178375-A1 Heteroaryloxy nitrogenous saturated heterocyclic derivative MSD K.K. (JP) 2006-08-10 US disclosed
EP-1642898-A1 HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-04-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178375-A1 Heteroaryloxy nitrogenous saturated heterocyclic derivative HRH3, HRH4, HCRTR2 KMT2A 423/4885KDM4E 1047/4885MAPT 3841/4885
US-20100210637-A1 HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE HRH3, HRH4, HRH2 KMT2A 552/4885KDM4E 1384/4885MAPT 4280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.